TY - JOUR AU - Hernández Rodríguez , DC AU - Monroy Sánchez , DC AU - Porras Ramírez, A. PY - 2021/06/14 Y2 - 2024/03/29 TI - Efficacy and safety of liraglutide for weight loss in adults: systematic review JF - Revista Colombiana de Endocrinología, Diabetes & Metabolismo JA - Rev.ACE VL - 7 IS - 4 SE - Original Articles DO - 10.53853/encr.7.4.651 UR - https://revistaendocrino.org/index.php/rcedm/article/view/651 SP - 250-257 AB - <p><strong><em>Objective:</em></strong><em> To evaluate the efficacy and safety of liraglutide as a coadjuvant medication to reduce the body mass index (BMI) in overweight (BMI: 25-30 kg/m<sup>2</sup>) and obesity (BMI: &gt; 30 kg/m<sup>2</sup>) worldwide. </em></p><p><strong><em>Materials and methods: </em></strong><em>A search of studies was carried out in several databases (TRIP, Embase, Pubmed, Scopus, Epistemonikos, Cochrane and ClinicalKey), the outcome evaluated was the decrease in weight with the use of liraglutide. We use the PRISMA 2009 tool in order to obtain a systematic review. </em></p><p><strong><em>Results: </em></strong><em>A total of 74 studies, 3 randomized clinical trials were included, evaluating 4281 participants. Weight loss was the main outcome, and adverse events were secondary outcomes. Meta-analysis was carried out with a weight loss report of -5.22 (95% confidence interval [CI]: - 5.95, -4.50), inconsistency index (I</em><em>²</em><em>) with high heterogeneity, as well as the meta-regression performed. Adverse events are evidenced more frequently in the liraglutide group, Gastrointestinal events were the most reported. </em></p><p><strong><em>Conclusion: </em></strong><em>The individual results in the studies demonstrate that the use of liraglutide reduces weight. However, this systematic review shows that there is no statistical significance of the evidence for heterogeneity of the studies evaluated.</em></p> ER -